pharma · Scabies · Bioequivalence trial in healthy volunteers
Alphapharm Pty Ltd
Alphapharm Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Scabies, Bioequivalence trial in healthy volunteers, moderate to severely inflamed candidiasis of the skin, Mild to mod
Phase 3 · small molecule · Acromegaly
Debio 4126 is a 12-week ready-to-use suspension formulation of octreotide, a somatostatin analog, being developed by Alphapharm Pty Ltd for the treatment of acromegaly. The program is currently in Phase 3 development, with an active randomized controlled trial (Debio 4126-301) comparing double-blind Debio 4126 against
Internal code Debio 4126-301
Debio 4126 is a 12-week ready-to-use suspension formulation of octreotide, a somatostatin analog, being developed by Alphapharm Pty Ltd for the treatment of acromegaly. The program is currently in Phase 3 development, with an active randomized controlled trial (Debio 4126-301) comparing double-blind Debio 4126 against placebo and open-label Debio 4126 in patients with acromegaly previously treated with somatostatin analogs. Octreotide is an established therapeutic class approved globally for acromegaly management; this formulation appears designed to offer an extended-release option with improved convenience. The sponsor's strategy focuses on demonstrating efficacy and safety in a pre-treated population, a common approach for reformulated somatostatin analogs. Regulatory approval timelines and commercial milestones have not yet been disclosed. Octreotide itself is approved in Australia (TGA), the European Union (EMA), and China (clinical trials ongoing), with multiple manufacturers including Novartis and Sun Pharma. The competitive landscape includes both somatostatin analogs and growth hormone receptor antagonists such as pegvisomant (SOMAVERT) and capromorelin (PALSONIFY).
Acromegaly is a rare endocrine disorder caused by excess growth hormone secretion, typically from a pituitary adenoma. The disease carries significant morbidity including cardiovascular complications, metabolic dysfunction, and reduced quality of life. Current treatment options include surgery, radiotherapy, and medical therapy with somatostatin analogs (octreotide, lanreotide) or growth hormone receptor antagonists. Many patients require long-term medical management, often with repeated injections or infusions. Extended-release formulations that reduce dosing frequency address a key unmet need in patient convenience and compliance, particularly in chronic disease management where treatment burden directly impacts adherence and outcomes. The acromegaly treatment market, while niche, represents significant commercial opportunity given the chronic nature of the disease and the need for durable, well-tolerated therapies. A 12-week formulation of octreotide could differentiate from existing monthly or bi-weekly somatostatin analog regimens. Competitive positioning depends on efficacy parity, safety profile, injection site tolerability, and cost-effectiveness relative to established therapies including SOMAVERT (pegvisomant), PALSONIFY (capromorelin), and existing octreotide/lanreotide formulations. The patient population—acromegaly sufferers previously treated with somatostatin analogs—represents a well-defined, treatment-experienced cohort where efficacy and tolerability data are most clinically relevant.
Drug Class: Somatostatin analog (systemic hormonal preparation, ATC H01)
Active Ingredient: Octreotide
Modality: Small molecule
Formulation: Ready-to-use suspension for injection; available in 30 mg, 60 mg, and 90 mg doses
Mechanism of Action: Not yet disclosed in available data; octreotide is a known somatostatin receptor agonist that suppresses growth hormone and insulin-like growth factor-1 (IGF-1) secretion
Target: Not yet disclosed; presumed somatostatin receptors (SSTR2, SSTR5)
Route of Administration: Not yet disclosed; likely subcutaneous or intramuscular injection based on formulation type
Related Therapies: Lanreotide (another somatostatin analog), pegvisomant (growth hormone receptor antagonist), capromorelin (ghrelin receptor antagonist)
First Approval (Octreotide): Approved in Australia from 1998 onwards; approved in EU; clinical trials ongoing in China
Patent Status: Not yet disclosed
Also known as: Growth hormone excess, pituitary giant, somatotroph adenoma
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
ClinicalTrials.gov lists 9 registered studies for Growth Hormone (AACT aggregate).
Phase breakdown: NA (6), PHASE3 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0019933), Orphanet — acromegaly, NCT00562796, NCT00966134, NCT01158612, NCT01540773, NCT04079010, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Debio 4126-301 Phase 3 trial active
Randomized 3-arm trial (double-blind Debio 4126, placebo control, open-label Debio 4126) assessing efficacy and safety of 12-week octreotide formulation in acromegaly patients previously treated with somatostatin analogs.
The acromegaly treatment landscape includes multiple approved therapies across different mechanisms. Somatostatin analogs dominate first-line medical therapy: octreotide (multiple manufacturers including Novartis, Sun Pharma, Generic Health in Australia) and lanreotide are established monthly or bi-weekly injectables. Pegvisomant (SOMAVERT, Pfizer) is a growth hormone receptor antagonist approved for acromegaly and represents an alternative mechanism for patients inadequately controlled on somatostatin analogs or intolerant to them. Capromorelin (PALSONIFY, Crinetics Pharmaceuticals) is a newer ghrelin receptor agonist recently approved, offering a distinct mechanism. Growth hormone replacement therapies such as GENOTROPIN GOQUICK and NSELTY address specific patient populations. Debio 4126 positions itself as an extended-release octreotide formulation (12-week dosing) within the established somatostatin analog class, targeting improved convenience and compliance versus existing monthly formulations. Competitive advantage hinges on demonstrated non-inferiority or superiority in efficacy, superior tolerability, and reduced injection burden. The competitive set also includes investigational agents and off-label uses of other hormonal therapies. Alphapharm's strategy appears focused on the pre-treated population, a segment where efficacy and safety data are most clinically relevant and where extended-release convenience offers tangible clinical benefit.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| INCRELEX | Lacuna Pharma Pty Ltd | — | approved |
| PALSONIFY | Crinetics Pharmaceuticals Europe GmbH | — | approved |
| GENOTROPIN GOQUICK | Pfizer Australia Pty Ltd | — | approved |
| SOMAVERT | Pfizer Australia Pty Ltd | — | approved |
| THYROGEN | Sanofi-aventis Healthcare Pty Ltd | — | approved |
| ORGOVYX | — | — | approved |
| ARX GANIRELIX | Alphapharm Pty Ltd | — | approved |
| NGENLA | Pfizer Australia Pty Ltd | — | approved |
| CETROTIDE | Merck KGaA, Darmstadt, Germany | — | approved |
| YSELTY | — | — | approved |
| SKYTROFA (PREVIOUSLY LONAPEGSOMATROPIN ASCENDIS PHARMA) | — | — | approved |
| SIGNIFOR | — | — | approved |
| PEGVISOMANT | — | Growth hormone receptor antagonist | Approved |
| PASIREOTIDE PAMOATE | — | Somatostatin receptor 2 agonist | Approved |
| OCTREOTIDE ACETATE | — | Somatostatin receptor agonist | Approved |
| LANREOTIDE ACETATE | — | Somatostatin receptor 2 agonist | Approved |
| BROMOCRIPTINE MESYLATE | — | D2-like dopamine receptor agonist | Approved |
| PASIREOTIDE | — | Somatostatin receptor 5 agonist | Phase 3 |
| PALTUSOTINE | — | Somatostatin receptor 2 agonist | Phase 3 |
| OCTREOTIDE | — | Somatostatin receptor agonist | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Australia (TGA): Octreotide is approved; multiple PBS listings (codes 10533J, 10543X, 10549F, 10550G, 10558Q, 10566D, 11501H, 11512X, 11537F, 11893Y) with first listings from 1998 onwards. Sponsors include Generic Health Pty Ltd, Novartis Pharmaceuticals Australia Pty Limited, and Sun Pharma ANZ Pty Ltd. Regulatory status of Debio 4126 formulation not yet disclosed.
European Union (EMA): Octreotide is approved under EMA product numbers EMEA/H/C/005826 (authorized 02/12/2022) and EMEA/H/C/006322 (authorized 02/12/2025), with marketing authorization holders Camurus AB and Amryt Pharmaceuticals DAC. Regulatory status of Debio 4126 formulation not yet disclosed.
China (NMPA): Octreotide is in clinical trials (NCT02409849). Regulatory status of Debio 4126 formulation not yet disclosed.
United States (FDA): Regulatory status not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
Debio 4126 Formulation: Development status and regulatory pathway not yet disclosed. Phase 3 trial is active.
Debio 4126 is an extended-release formulation of octreotide, a somatostatin analog, being developed for the treatment of acromegaly. It is designed as a 12-week injectable suspension, offering less frequent dosing than existing monthly octreotide formulations.
Acromegaly is a rare endocrine disorder caused by excess growth hormone secretion, typically from a pituitary adenoma. It causes significant morbidity including cardiovascular complications, metabolic dysfunction, and reduced quality of life. Long-term medical management is often required to suppress growth hormone and IGF-1 levels.
Octreotide is a somatostatin analog that binds to somatostatin receptors (particularly SSTR2 and SSTR5) on pituitary cells, suppressing growth hormone secretion and reducing circulating IGF-1 levels, thereby controlling acromegaly symptoms and complications.
Debio 4126 is being developed by Alphapharm Pty Ltd, an Australian pharmaceutical company. No development partner or license arrangement has been disclosed.
Debio 4126 is currently in Phase 3 clinical development. The active trial (Debio 4126-301) is a randomized 3-arm study comparing double-blind Debio 4126, placebo, and open-label Debio 4126 in acromegaly patients previously treated with somatostatin analogs.
The Phase 3 trial (Debio 4126-301) is a randomized 3-arm, double-blind, placebo-controlled study with an open-label arm. It assesses efficacy and safety of the 12-week octreotide formulation in patients with acromegaly who have prior somatostatin analog treatment experience.
The trial enrolls patients with acromegaly who have been previously treated with somatostatin analogs, representing a treatment-experienced population with demonstrated tolerance to this drug class.
Yes, octreotide is approved for acromegaly in multiple jurisdictions. It is approved in Australia (TGA) with multiple PBS listings since 1998, in the European Union (EMA), and is in clinical trials in China. Multiple manufacturers produce octreotide, including Novartis, Sun Pharma, and Generic Health.
A 12-week formulation reduces dosing frequency compared to existing monthly or bi-weekly octreotide/lanreotide injections, potentially improving patient convenience, compliance, and quality of life in this chronic disease requiring long-term management.
Competitors include somatostatin analogs (lanreotide, existing octreotide formulations), pegvisomant (SOMAVERT, a growth hormone receptor antagonist), capromorelin (PALSONIFY, a ghrelin receptor agonist), and growth hormone replacement therapies. Debio 4126 competes primarily within the somatostatin analog class.
Regulatory approval status for Debio 4126 has not yet been disclosed. The program is in Phase 3 development; no approvals in Australia, the EU, US, China, or Japan have been announced.
Approval timelines have not yet been disclosed. The Phase 3 trial is currently active; regulatory submission and approval dates are not yet known.
Octreotide is a somatostatin receptor agonist that suppresses growth hormone and IGF-1 secretion by binding to somatostatin receptors on pituitary cells, thereby controlling acromegaly.
Debio 4126 is available as a ready-to-use suspension in 30 mg, 60 mg, and 90 mg doses.
No development partner or licensing arrangement has been disclosed for Debio 4126. Alphapharm Pty Ltd is the sole sponsor.
The route of administration has not yet been disclosed; however, based on the formulation type (ready-to-use suspension), it is likely administered as a subcutaneous or intramuscular injection.
The primary endpoints of the Phase 3 trial have not yet been disclosed in available data.
Debio 4126-301 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Debio 4126 represents a reformulation strategy within an established drug class, targeting the convenience-driven segment of acromegaly patients. Extended-release formulations (12-week dosing) address a genuine unmet need in chronic disease management where treatment burden impacts adherence. Alphapharm's focus on pre-treated patients is clinically sound, as this population has demonstrated somatostatin analog tolerance and provides a well-defined efficacy benchmark.
Competitive Implications: Success depends critically on demonstrating non-inferiority to existing monthly octreotide/lanreotide formulations with superior tolerability or convenience. The competitive threat from newer mechanisms (capromorelin, pegvisomant) is moderate; Debio 4126 competes within the somatostatin analog class rather than displacing alternative mechanisms. Market share gains would likely come from existing octreotide/lanreotide patients seeking less frequent dosing.
Regulatory Pathway: Phase 3 trial design (placebo-controlled, double-blind) suggests a traditional efficacy and safety pathway. Approval timelines and regulatory jurisdiction priorities remain undisclosed. Octreotide's established safety profile may support expedited review if efficacy is demonstrated.
Future Catalysts: Phase 3 trial completion and topline efficacy/safety data release; regulatory submissions (anticipated jurisdictions: Australia, EU, potentially US); approval decisions; commercial launch and market penetration data. Patent exclusivity and manufacturing scale-up timelines are not yet disclosed.
Commercial Considerations: Acromegaly is a rare disease with limited patient population; market size is niche but stable. Pricing and reimbursement will depend on demonstrated clinical benefit versus existing therapies. Success metrics include market share capture from existing somatostatin analog users and potential label expansion to treatment-naïve patients post-approval.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.